Sign in
CompletedEarly phase 1

Pharmacokinetics of Atropine Oral Gel

Key facts

Who runs it
University of Utah
Where
Salt Lake City, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
10 people enrolled
Started
1 Oct 2022
Ended
10 Dec 2024
Type of study
Interventional
Treatments tested
  • Atropine sulfate gel (0.01%)
Record updated
18 December 2024

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Provide written informed consent and authorization
  • Study participants must be able to complete consent, and all study evaluations written in the English language

Who cannot take part

  • Chemotherapy or radiotherapy treatment within the last three months
  • Previous head and/or neck radiotherapy
  • Treatment with any other investigational drug during the 30 days prior to enrollment into the study
  • Patients receiving anticholinergic medications at baseline
  • Patients who are receiving immunosuppression
  • Patient taking monoamine oxidase inhibitors
  • Patients with a history of hypersensitivity reaction towards atropine and/or Carbopol 980 NF or any carbomers
  • Patients with heart conditions such as congenital heart disease, heart failure, coronary heart disease, myocardial infarction, and arrhythmia
  • Patients with partial pyloric stenosis or other diseases related to gastrointestinal obstruction
  • Patients who are actively being treated for an infection
  • Patients with a history of salivary gland obstruction or stones
  • Patients with a history of chronic lung disease or chronic obstructive pulmonary disease (COPD)
  • Severe renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated using the CKD-EPI creatinine equation:; eGFR (mL/min/1.73 m2) = 141 x min(Scr/k, 1)α x max(Scr/k,1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black]; Where,; k=0.7 if female; k=0.9 if male; α=-0.329 if female; α=-0.411 if male; min=The minimum of Scr/k or 1; max=The maximum of Scr/k or 1; Scr = serum creatinine (mg/dL)
  • Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility:; Bilirubin > 3 x upper limit of normal (ULN). [ULN for bilirubin = 1.4 mg/dL]; Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 3 x ULN values used by the laboratory performing the test. [ULN for AST = 40 U/L, ULN for ALT = 60 U/L]; Alkaline phosphatase (ALP) > 3 x ULN [ULN for ALP = 126 U/L)
  • Female subjects who are pregnant or nursing at the time of screening
  • Deforming lesions of the oral cavity
  • Patients with acute glaucoma that may be exacerbated with atropine administration
  • Patients diagnosed with urinary retention
  • Patients with an artificial airway (tracheostomy)

Where in United States

  • University of UtahSalt Lake City, United States

About the trial

What the trial wants to find out

To evaluate the single-dose pharmacokinetics of atropine gel formulation after topical administration in the oral cavity of healthy adults.

The group in the trial

  • 0.1 mg of atropineTreatment being tested

    1 gram of gel by topical application in the oral cavity once.

    Treatment: Atropine sulfate gel (0.01%)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Single-Dose Pharmacokinetics of Atropine Oral Gel in Healthy Adults
Record updated
18 December 2024
Pharmacokinetics of Atropine Oral Gel (NCT05164367) – Frontlight Research